Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

19 avr. 2021 07h30 HE | Source: Biogen Inc.

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA® (nusinersen)Additional research reinforces the potential of...
16 avr. 2021 07h30 HE | Source: Biogen Inc.

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

New findings from MS PATHS show that treatment with TYSABRI® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus® (ocrelizumab)Real-world data from...
15 avr. 2021 16h30 HE | Source: Biogen Inc.

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needsMore than 500,000 individuals worldwide living with...
14 avr. 2021 16h06 HE | Source: Biogen Inc.

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease...
09 avr. 2021 16h30 HE | Source: Biogen Inc.

Biogen Announces Two New Nominees for Election to Board of Directors

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscienceCompany thanks Director Robert W. Pangia as he retires from the Board ...
08 avr. 2021 07h00 HE | Source: Biogen Inc.

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA® (tocilizumab)Biosimilars have the potential...
07 avr. 2021 07h30 HE | Source: Biogen Inc.

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option...
04 mars 2021 07h47 HE | Source: Biogen Inc.

Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina

The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolioThe new facility is expected to employ approximately 90 people and to be...
24 févr. 2021 07h30 HE | Source: Biogen Inc.

Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program

$170,000 grants will fill critical gap for 3,000 food insecure families in Greater Boston via Food For Free’s new grocery box program CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Life...
11 févr. 2021 08h03 HE | Source: Biogen Inc.

Biogen Announces the Expiration Date Results of Its Cash Tender Offer

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the expiration date results of its previously announced offer to purchase for cash (the...

Page précédente